Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study-Reference-Cited by-同舟云学术

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Published:2024-01 Issue:1 Volume:25 Page:117-125
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Song Yuqin,Malpica Luis,Cai Qingqing,Zhao Weili,Zhou Keshu,Wu Jianqiu,Zhang Huilai,Mehta-Shah Neha,Ding Kaiyang,Liu Yao,Li Zengjun,Zhang Liling,Zheng Meifang,Jin Jie,Yang Haiyan,Shuang Yuerong,Yoon Dok Hyun,Gao Sujun,Li Wenyu,Zhai Zhimin,Zou Liqun,Xi Yaming,Koh Youngil,Li Fei,Prince Miles,Zhou Hui,Lin Lie,Liu Hui,Allen Pamela,Roncolato Fernando,Yang Zhenfan,Kim Won-Seog,Zhu Jun

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes;Vose;J Clin Oncol,2008

2. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project;Bellei;Haematologica,2018

3. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study;O'Connor;J Clin Oncol,2011

4. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy;Coiffier;J Clin Oncol,2012

5. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study;O'Connor;J Clin Oncol,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case of recalcitrant folliculotropic mycosis fungoides successfully treated by abrocitinib;International Journal of Dermatology;2024-09-09

2. Next Questions in Peripheral T-Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Computational identification and experimental validation of potential inhibitors of JAK1 kinase from natural source for the effective treatment of colorectal adenocarcinoma;South African Journal of Botany;2024-08

4. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

5. Failing Forward in Peripheral T-Cell Lymphoma;Journal of Clinical Oncology;2024-05-10